Nasdaq-100 & Gossamer Bio

Nasdaq-100: Gossamer Bio has not met the minimum share bid price required for continued listing on the Nasdaq Global Select Market, indicating a potential delisting.

Gossamer Bio: Gossamer Bio is the defendant in multiple class action lawsuits following the failure of its Phase 3 PROSERA study, which led to an 80% drop in its stock price and potential delisting from Nasdaq-100. The lawsuits allege securities fraud due to undisclosed issues with the trial design.

Nasdaq-100: Nasdaq-100 is the stock exchange where Gossamer Bio's shares are traded, providing the platform for its public listing.

Gossamer Bio: Gossamer Bio initiated an exchange offer for its Existing Convertible Notes to reduce debt and improve its financial structure, which is expected to have a positive impact on the company's financial health.